Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01122888
First received: January 12, 2010
Last updated: July 22, 2014
Last verified: April 2014

January 12, 2010
July 22, 2014
December 2009
September 2012   (final data collection date for primary outcome measure)
Change in serum VEGFR2 [ Time Frame: Over 14 days from the end of sunitinib to the end of course 1 ] [ Designated as safety issue: No ]
Change in serum VEGFR2 over the 14-day interval from the end of sunitinib malate administration to the end of course 1 [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01122888 on ClinicalTrials.gov Archive Site
  • Comparison of the change in serum VEGFR2 in courses 1 and 2 [ Time Frame: Over 14 days ] [ Designated as safety issue: No ]
    Compared using a paired t-test.
  • Toxicity rates, graded using the NCI CTCAE version 4.0 [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: Yes ]
    Compared using chi-squared tests or Fisher exact tests, as appropriate.
  • Response rate evaluated using RECIST criteria [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: No ]
    Summarized by type, grade, and attribution and compared using chi-squared tests or Fisher exact tests, as appropriate.
  • Serum type I collagen c-telopeptide crosslink measurements [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: No ]
  • Progression-free survival [ Time Frame: Assessed up to 30 days after completion of study treatment ] [ Designated as safety issue: No ]
    Estimated using the Kaplan-Meier method. Summarized by type, grade, and attribution and compared using chi-squared tests or Fisher exact tests, as appropriate.
  • Change in serum VEGFR2 in course 1 vs 2 [ Designated as safety issue: No ]
  • Safety [ Designated as safety issue: Yes ]
  • Efficacy [ Designated as safety issue: No ]
  • Serum type I collagen c-telopeptide crosslink measurements at the end of sunitinib malate vs at the end of each course [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
Pilot Biomarker Study of the Integrin AlphavBeta3 Antagonist Cilengitide (EMD121974) in Combination With Sunitinib

This clinical trial is studying how well giving cilengitide together with sunitinib malate works in treating patients with advanced solid tumors or glioblastoma multiforme. Cilengitide and sunitinib malate may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cilengitide together with sunitinib malate may kill more tumor cells. Studying samples of blood in the laboratory from patients receiving cilengitide and sunitinib malate may help doctors understand the effect of these drugs on biomarkers.

PRIMARY OBJECTIVES:

I. Determine the effect of cilengitide on changes in serum VEGFR2, a pharmacodynamic biomarker of sunitinib malate effects on endothelial function, during the withdrawal phase of a course of sunitinib malate in patients with advanced solid tumors or glioblastoma multiforme.

SECONDARY OBJECTIVES:

I. Determine the effect of cilengitide exposure on changes in VEGFR2 over the 14-day interval from the end of sunitinib malate administration to the end of course 1 in these patients.

II. Test the safety and efficacy of this regimen in these patients. III. Develop serum collagen c-telopeptide crosslinks (CTx) as a pharmacodynamic marker for cilengitide.

OUTLINE:

COURSE I: Patients receive oral sunitinib malate on days 1-14 (weeks 1-2). Patients are then randomized to 1 of 2 treatment arms.

ARM I: Patients receive cilengitide IV over 1 hour twice in weeks 3 and 4.

ARM II: Patients do not receive treatment in weeks 3 and 4.

COURSE II: Patients in both arms then receive oral sunitinib malate on days 1-14 and cilengitide IV over 1 hour twice in weeks 3 and 4. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up periodically.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Adult Giant Cell Glioblastoma
  • Adult Glioblastoma
  • Adult Gliosarcoma
  • Recurrent Adult Brain Tumor
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Drug: cilengitide
    Given IV
    Other Name: EMD 121974
  • Other: clinical observation
    Patients undergo a 2-week rest period
    Other Name: observation
  • Other: laboratory biomarker analysis
    Correlative studies
  • Experimental: Arm I (course 1)
    Patients receive cilengitide IV over 1 hour twice weekly for 2 weeks.
    Interventions:
    • Drug: cilengitide
    • Other: laboratory biomarker analysis
  • Arm II (course 1)
    Patients do not receive treatment and undergo a 2-week rest period.
    Interventions:
    • Other: clinical observation
    • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
41
Not Provided
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed solid tumor or malignant glioblastoma multiforme meeting >= 1 of the following criteria:

    • Disease refractory to standard therapy
    • No standard therapy exists
    • Sunitinib malate monotherapy would be appropriate management
  • Measurable disease is not required
  • Previously treated brain metastases or primary brain neoplasms allowed provided patient is not receiving concurrent corticosteroids
  • Karnofsky performance status 70-100%
  • Absolute neutrophil count (ANC) >= 1,500/μL
  • White blood cell count (WBC) >= 3,000/μL
  • Platelet count >= 100,000/μL
  • Hemoglobin >= 9 g/dL
  • Total bilirubin normal (unless due to documented Gilbert syndrome)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal (ULN) (< 5 times ULN in the presence of liver metastases)
  • Creatinine normal OR creatinine clearance >= 60 mL/min
  • Serum calcium =< 12.0 mg/dL
  • QTc < 500 msec
  • Patients with any of the following are allowed provided they have New York Heart Association (NYHA) class I-II cardiac function and undergo a baseline echocardiogram (ECHO)/multiple gated acquisition (MUGA):

    • History of class II heart failure and asymptomatic on treatment
    • Prior anthracycline exposure
    • Previously treated with central thoracic radiotherapy that included the heart in the radiotherapy port
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib malate
  • No concurrent uncontrolled illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Psychiatric illness and/or social situation that would limit compliance with study requirements
  • No pre-existing thyroid abnormality for which thyroid function cannot be maintained in the normal range with medication
  • No documented thrombosis (pulmonary embolism or deep vein thrombosis) within the past 6 months
  • No known coagulopathy or thrombophilia
  • No proven gastric or duodenal ulcer or clinically significant gastrointestinal (GI) blood loss within the past 6 weeks
  • No history of central nervous system (CNS) hemorrhage
  • No life-threatening bleeding diathesis within the past 6 months
  • No history of serious ventricular arrhythmia (i.e., ventricular fibrillation or ventricular tachycardia >= 3 beats in a row) or other significant electrocardiogram (ECG) abnormalities
  • No poorly controlled hypertension (i.e., systolic blood pressure (BP) >= 150 mm Hg or diastolic BP >= 100 mm Hg)
  • No condition that would impair the ability to swallow and retain sunitinib malate tablets, including any of the following:

    • GI tract disease resulting in an inability to take oral medications or a requirement for IV alimentation
    • Prior surgical procedures affecting absorption
    • Active peptic ulcer disease
  • No gastrostomy, jejunostomy, or other forms of enteral tube feeding modalities
  • None of the following conditions:

    • Serious or non-healing wound or ulcer
    • Abdominal fistula, GI perforation, or intra-abdominal abscess within the past 28 days
    • Cerebrovascular accident or transient ischemic attack within the past 12 months
    • Myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within the past 12 months
    • NYHA class III or IV heart failure
    • Radiographically or physiologically diagnosed usual interstitial pneumonitis (UIP) or non-specific interstitial pneumonitis (NSIP)
  • No bone fracture within the past 12 months
  • No other concurrent anticancer agents or therapies
  • More than 4 weeks since prior radiotherapy or systemic antineoplastic therapy (6 weeks for nitrosoureas, mitomycin C, or bevacizumab) and recovered
  • More than 2 weeks since prior hormone replacement therapy or hormonal contraceptives
  • More than 1 month since prior surgery
  • At least 7 days since prior and no concurrent CYP3A4 inhibitors
  • At least 12 days since prior and no concurrent CYP3A4 inducers
  • Prior luteinizing hormone-releasing hormone agonists for hormone-refractory prostate cancer allowed
  • Prior antiangiogenic agents (e.g., sorafenib, pazopanib, AZD2171 [cediranib maleate], PTK787 [vatalanib], or VEGF Trap [ziv-aflibercept]) allowed provided there is no disease progression
  • No prior cilengitide or sunitinib malate
  • No prior bevacizumab
  • No other concurrent investigational agents
  • No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients
  • No concurrent agents with proarrhythmic potential (e.g., terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, or flecainide)
  • No concurrent palliative radiotherapy
  • No other concurrent chemotherapy or biologic agents
  • No concurrent medications that may cause QTc prolongation
  • No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin)

    • Up to 2 mg of daily warfarin for the prophylaxis of thrombosis allowed
    • Low-molecular weight heparin allowed provided prothrombin time (PT)/international normalized ratio (INR) =< 1.5
  • No concurrent grapefruit juice
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01122888
NCI-2011-01455, NCI-2011-01455, CDR0000659080, UCCRC-09-259-A, 09-259-A, 8313, U01CA069852, P30CA014599
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Michael Maitland University of Chicago
National Cancer Institute (NCI)
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP